Author index

Abbott, Alison, see Weston, Arthur H. 283
Abbott, Alison, Can animal models really predict anxiety? 157
Ahlenius, Sven, see Danysz, Wojciech 45
Aktories, Klaus, Bärmann, Michael, Chhatwal, Gursharan, S. and Presek, Peter, New class of microbial toxins ADP-ribosylates actin 158
Albert, Adrien, The behaviour of foreign substances in the human body 258
Alexis, M. N., Glucocorticoids: new insights into their molecular mechanisms 10
Archer, Trevor, see Danysz, Wojciech 45
Archer, Trevor, Towards animal models of mental retardation 165

Bärmann, Michael, see Aktories, Klaus 158
Barnes, Peter J., Airway neuropeptides and asthma 24
Barnes, Peter J. and Fan Chung, K., PAF closely mimics pathology of asthma 285
Barron, Sarah E. and Guth, Paul S., Uses and limitations of strychnine as a probe in neurotransmission 204
Bayley, Hagan, Gasparro, Francis and Edelson, Richard, Photoactivatable drugs 138
Beal, Jack L., see Patil, Potat N. 327
Becker, Cord-Michael and Betz, Heinrich, Strychnine: useful probe or not? 379
Beckeringh, Jan Jacob, see Brodde, Otto-Erich 403
Beer, Bernard, see Heyman, Gene M. 388
Bertoncello, I. and Bradley, T. R., Human cell cultures for screening anti-cancer drugs 249
Betz, Heinrich, see Becker, Cord-Michael 379
Birnbaumer, Lutz, Which G protein subunits are the active mediators in signal transduction? 209
Black, J. W. and Shankley, N. P., How does gastrin act to stimulate oxyntic cell secretion? 484
Boger, Joshua, Clinical goal in sight for small molecule renin inhibitors 370
Bonjour, Jean-Phillipe, see Hirschel-Scholz, Suzanne 246
Bonser, R. W., see Garland, L. G. 334
Botting, R. M., see Vane, J. R. 489
Boucher, R. C., see Waltner, W. E. 316
Bradley, T. R., see Bertoncello, I. 249
Brändström, Arne, see Lindberg, Per 399
Brendel, Klaus, Gandolfi, A. Jay, Krumdieck, Carlos L. and Smith, Peter F., Tissue slicing and culturing revisited 11
Briley, Mike, see Chopin, Philippe 383
Brodde, Otto-Erich, Beckeringh, Jan Jacob and Michel, Martin Christian, HUMANS V. ANIMALS: HUMAN HEART β-adrenoceptors: a fair comparison with lymphocyte β-adrenoceptors? 403
Burns, J. J., Celebrating one hundred issues 453

Catterall, William A., Common modes of drug action on Na^+ channels: local anesthetics, antiarrhythmics and anticonvulsants 57
Changeux, Jean-Pierre, Giraudaut, Jerôme and Dennis, Michael, The nicotinic acetylcholine receptor: molecular architecture of a ligand-regulated ion channel 457
Chhatwal, Gursharan S., see Aktories, Klaus 158
Chopin, Philippe and Briley, Mike, Animal models of anxiety: the effect of compounds that modify 5-HT neurotransmission 383
Clarke, Paul B. S. Recent progress in identifying nicotinic cholinoceptors in mammalian brain 32
Cohen, Sasson and Sokolovsky, Mordechai, Complexity apparent in muscarinic mechanisms 41
Colquhoun, David, see Ogden, David C. 294
Colquhoun, David, Ogden, David C. and Mathie, Alistair, Nicotinic acetylcholine receptors of nerve and muscle: functional aspects 463
Colquhoun, David, see Ogden, David 335
Cooper, Steven J., Kirkham, Tim C. and Estall, Lorna B., Pyrazoloquinolines: second generation benzodiazepine receptor ligands have heterogeneous effects 180
Cooper, Steven J. and Neill, Joanna C., 5-HT receptors and the sweet tooth 199
Cordiner, Stephen J., see Jordan, T. William 144
Cottrell, G. A., see Lambert, J. J. 224
Cowen, P. J., Psychotropic drugs and human 5-HT neuroendocrinology 105
Cull-Candy, Stuart, G., and Usowicz, Maria M., Patch-clamp recording from single glutamate receptor channels 218
Cuomo, Vincenzo, Perinatal neurotoxicology of psychotropic drugs 346
Curtis, David R., and Gynther, Bruce D., Selective $GABA_A$ antagonists? 90

Damiano, Victor V., see Weinbaum, George 6
Danysz, Wojciech, Fowler, Christopher, J., Ahlenius, Sven and Archer, Trevor, 'Selective' lesions of brain neurotransmitters can be misleading 45
De Clercq, Erik, New selective anti-viral agents active against the AIDS virus 339
DeBlasi, Antonio and Motulsky, Harvey J., Alternative molecular interpretations of binding curves: compelling competition 421
DeFeudis, F. V., Interactions of Ca^{2+} antagonists at 5-HT_2 and H_2 receptors and GABA uptake sites 200
Delbro, D. and Nordström, O., Adenosine-induced bronchoconstriction 52
Dennis, Michael, see Changeux, Jean-Pierre 457
di Marzo, Vincenzo, Tippins, John R. and Morris, Howard R., Dual role of neuropeptidergic system in pathology of asthma? 168
Dickson, R. B., see Wolff, B. 119
Dickson, R. B., Rosen, N., Gelman, E. P. and Lippman, M. E., Receptor-and signal transduction-related proto-oncogenes in breast cancer 372
Docherty, Jim, A premature proposal? 123
Docherty, James R., The use of the human saphenous vein in pharmacology 358
Dougan, Donald, Wade, Denis and Duffield, Patricia, How metabolites may augment some psychostimulant actions of amphetamine 277
Dourish, C. T. and Hill, D. R., Classification and function of CCK receptors 207
Dreher, Kuba, see Jackson, David M. 419
Drummond, Alan H., Lithium and inositol lipid-linked signalling mechanisms 129
Duffield, Patricia, see Dougan, Donald 277

Edelson, Richard, see Bayley, Hagan 138
Edvinsson, L., Håkanson, R., Wahlestedt, C. and Uddman, R., Effects of neuropeptide Y on the cardiovascular system 231
Edwards, I. Ralph, Monitoring for drug safety 52
Elbrink, J., Malhotra, S. K. and Elleker, M. G., FOCUS ON DISEASE: Duchenne muscular dystrophy: pathogenesis and pharmacology 109
Elleker, M. G., see Elbrink, J. 100
Enna, S. J., and Karbon, E. W., Receptor regulation: evidence for a relationship between phospholipid metabolism and neurotransmitter receptor-mediated cAMP formation in brain 21
Erdmann, Erland, see Schmitz, Wilhelm 447
Estall, Lorna B., see Cooper, Steven J. 180
Etienne, Pierre E. and Zubensko, George S., Does captopril elevate mood? 329

Fan Chung, K., see Barnes, Peter J. 285
Farmer, Stephen G., Airway smooth muscle responsiveness: modulation by the epithelium 8
Fent, Karl, and Zbinden, Gerhard, Toxicity of interferon and interleukin 100
Ferry, David R., see Glossmann, Hartmut 95
Flavahan, N. A. and Vanhoutte, P. M., Flavahan and Vanhoutte reply 124
Fleckenstein, A., Frey, M., Zorn, J. and Fleckenstein-Grün, G., The role of calcium in the pathogenesis of experimental arteriosclerosis 494
Fleckenstein-Grün, G., see Fleckenstein, A. 494
Fleming, William W., see Rice, Peter J. 332
Foster, A. C., see Kemp, J. A. 414
Fowler, Christopher J., see Danysz, Wojciech 45
Fozard, J. R., 5-HT_3 receptors and cytotoxic drug-induced vomiting 44
Fozard, J. R., 5-HT: The Enigma Variations 499
Franks, N. P. and Lieb, W. R., What is the molecular nature of general anaesthetic target sites? 169
Fraser, Claire M., see Kerlavage, Anthony R. 426
Frey, M., see Fleckenstein, A. 494

Gandolfi, A. Jay, see Brendel, Klaus 11
García-Sáinz, J. Adolfo, Angiotensin II receptors: one type coupled to two signals or receptor subtypes? 48
Garland, L. G., Bonser, R. W. and Thompson, N. T., Protein kinase C inhibitors are not selective 334
Gasparro, Francis, see Bayley, Hagan 138
Gatzy, J. T., see Waltner, W. E. 316
Gelmann, E. P. see Dickson, R. B. 372
Gerkens, John F., Does furosemide have vasodilator activity? 254
Gibb, Alisdair J., see Ogden, David C. 294
Gibb, Alasdair, see Ogden, David 335
Gill, R., see Kemp, J. A. 414
Gilman, Alfred G., see Graziano, Michael P. 476
Giraudat, Jerôme, see Changeux, Jean-Pierre 457
Girre, Catherine, see Thomas, Guy 292
Glaser, Thomas, see Traber, Jörg 432
Glossmann, Hartmut, Ferry, David R., Striessnig, Jörg, Goll, Alexandra and Moosburger, Kurt, Resolving the structure of the Ca^{2+} channel by

photoaffinity labelling 95
Gold, Geoffrey H. and Nakamura, Tadashi, Cyclic nucleotide-gated conductances: a new class of ion channels mediates visual and olfactory transduction 312
Goldstein, Avram, Binding selectivity profiles for ligands of multiple receptor types: focus on opioid receptors 454
Goll, Alexandra, see Glossmann, Hartmut 95
Graziano, Michael P. and Gilman, Alfred G., Guanine nucleotide-binding regulatory proteins: mediators of transmembrane signalling 476
Green, Jack Peter, Nomenclature and classification of receptors and binding sites: the need for harmony 90
Green, Jack Peter, Polypharmic antagonists – a class of their own 377
Greengard, Paul, see Huganir, Richard 470
Gryglewski, R. J., see Vane, J. R. 489
Guth, Paul S., see Barron, Sarah E. 204
Gynther, Bruce D., see Curtis, David R. 90

Hagiwara, Masatoshi, see Hidaka, Hiroyoshi 162
Håkanson, R., see Edvinsson, L. 231
Hanover, J. A., see Wolff, B. 119
Harrison, Neil L., Progesterone metabolites enhance GABA activities 334
Heise, George A., Facilitation of memory and cognition by drugs 65
Herman, A. G., see Moncada, S. 365
Hess, George P., see Udgaonkar, Jayant B. 190
Hess, George P., and Udgaonkar, Jayant B., Voltage-dependent inhibition of the acetylcholine receptor 335
Heyman, Gene M. and Beer, Bernard, A new approach for evaluating the behavioral effects of anti-psychotic drugs 388
Hidaka, Hiroyoshi and Hagiwara, Masatoshi, Pharmacology of the isoquinoline sulfonamide protein kinase C inhibitors 162
Hill, D. R., see Dourish, C. T. 207
Hirschel-Scholz, Suzanne and Bonjour, Jean-Phillipe, Radioprotective agent WR2721 opens new perspective in treatment of hyperparathyroidism and hypercalcemia 246
Hoffman, Brian B., see Thomas, John M. 308
Hofmann, Franz, Nastainczyk, Wolfgang, Röhrkasten, Axel, Schneider, Toni and Sieber, Manfred, Regulation of the L-type calcium channel 393
Hokin, Lowell E., The road to the phosphoinositide-generated second messengers 53
Hollenberg, Morley D., SARs: the receptor side of the coin 197
Houben, John J. G., Two new thrombolytic agents give 'striking results' 1
Hruby, Victor J., Implications of the X-ray structure of deamono-oxytocin to agonist/antagonist-receptor interactions 336
Huganir, Richard and Greengard, Paul, Regulation of receptor function by protein phosphorylation 470

Ikarashi, Yasushi, see Maruyama, Yuji 84
Izquierdo, Ivan, Sweet and bittersweet memories 83
Izquierdo, Ivan, On leaving drunks alone 161
Izquierdo, Ivan, The pathogenesis of the amnesia of Alzheimer's disease 325
Izquierdo, Ivan, see Netto, Carlos A. 415

Jackson, David M., Dreher, Kuba and Ross, Svante B., D_1 and D_2 dopamine agonist synergism and the nucleus accumbens 419
Jarrott, Bevyn, and Lewis, Stephen J. Discontinuation syndrome in rate chronically treated with centrally acting α-adrenoceptor agonists 244
Jarvis, Michael F. and Williams, Michael, Adenosine and dopamine function in the CNS 330
Jin Guo-zhang, (−)-Tetrahydropalmatine and its analogues as new dopamine receptor antagonists 81
Johnson, M. K. and Lotti, Marcello, Receptor or enzyme: the puzzle of NTE and organophosphate-induced delayed polyneuropathy 174
Jordan, T. William and Cordiner, Stephen J., Fungal epipolythiodioxopiperazine toxins have therapeutic potential and roles in disease 144

Karbon, E. W., see Enna, S. J. 21
Kemp, J. A., Foster, A. C., Gill, R. and Woodruff, G. N., MK-801, NMDA receptors and ischaemia-induced neurodegeneration 414
Kenakin, Terry, Agonists, partial agonists, antagonists, inverse agonists and agonist/antagonists? 423
Kerlavage, Anthony R., Fraser, Claire M. and Venter, J. Craig, Muscarinic cholinergic receptor structure: molecular biological support for subtypes 426
Khan, Manzoor M., see Melmon, Kenneth L. 437
Kirkham, Tim C., see Cooper, Steven J. 180
Kitchen, I., Statistics and pharmacology: the Bloody Obvious Test 252
Kitchen, Ian, Ian Kitchen replies 420
Klockgether, Thomas, Turski, Lechoslaw and Sontag, Karl-Heinz, A more expansive interpretation 20
Knowles, M. R., see Waltner, W. E. 316
Krumdieck, Carlos L., see Brendel, Klaus 11
Kulkarni, Prasad and Srinivasan, B. D., Ocular inflammation: a pharmacological model 375

Lakey, Trevor, Scientists and animal welfare 380
Lambert, J. J., Peters, J. A. and Cottrell, G. A., Actions of synthetic and endogenous steriods on the $GABA_A$ receptor 224
Langston, J. William, Closer to Parkinson's disease: MPTP and the aging nervous system 7
Leaver, David, Veterinary toxicology in Australia 262
Lee, Ta-Jyh, Synthesis, SARs and therapeutic potential of HMG-CoA reductase inhibitors 442
Leroy Blank, C., see Maruyama, Yuji 84
Levitan, Edwin, Hormones and behavior 380
Levitzki, Alexander, Regulation of hormone-sensitive adenylate cyclase 299
Lewis, Steven J., see Jarrott, Bevyn 244
Lieb, W. R., see Franks, N. P. 169
Lindberg, Per, Brändström, Arne and Wallmark, Björn, Structure-activity relationships of omeprazole analogues and their mechanism of action 399
Lippman, M. E., see Dickson, R. B. 372
Lodge, David, Modulating glutamate pharmacology 243
Lotti, Marcello, see Johnson, M. K. 174

MacDonald, Ewan and Saano, Veijo, Video teaching – glamour without effect 77
Malhotra, S. K., see Elbrink, J. 100
Marley, Philip D., New insights into the non-nicotinic regulation of adrenal medullary function 411
Maruyama, Yuji, Ikarashi, Yasushi and Leroy Blank, C., Recent developments in the determination of acetylcholine and choline 84
Mathie, Alistair, see Colquhoun, David 463
Max, B. This and that: risk and resurrection 16
Max, B. This and that: on method and muricide 87
Max, B. This and that: Helen's heart and plaster of Paris 166
Max, B. This and that: survival and certainty 290
Max, B. This and that: on books and belle donne, antimony and anti-caffeine 416
Melmon, Kenneth L. and Khan, Manzoor M., Histamine and its lymphocyte-selective derivatives as immune modulators 437
Michel, Martin Christian, see Brodde, Otto-Erich 403
Molenaar, P., see Summers, R. J. 272
Moncada, S., Herman, A. G. and Vanhoutte, P., Endothelium-derived relaxing factor is identified as nitric oxide 365
Moosburger, Kurt, see Glossmann, Hartmut 95
Morgan, Noel G., Regulation of insulin secretion by α_2-adrenergic agonists 369
Morris, Howard, R., see di Marzo, Vincenzo 168
Motulsky, Harvey J., see DeBlasi, Antonio 421

Nakamura, Tadashi, see Gold, Geoffrey H. 312
Nastainczyk, Wolfgang, see Hofmann, Franz 393
Neill, Joanna C., see Cooper, Steven J. 199
Netto, Carlos A. and Izquierdo, Ivan, Remembering the gut–brain connection 415
Nicholson, Anthony N., New antihistamines free of sedative side-effects 247
Nordström, O., see Delbro, D. 52

O'Donnell, Stella R. and Wanstall, Janet C., Functional evidence for differential regulation of β-adrenoceptor subtypes 265
Ogden, David C., Colquhoun, David and Gibb, Alisdair, J., Regulation of the acetylcholine receptor 294
Ogden, David, Colquhoun, David and Gibb, Alasdair, Ogden *et al.* reply 335
Ogden, David C., see Colquhoun, David 463
Otsuka, Masanori and Yanagisawa, Mitsuhiko, Does substance P act as a pain transmitter? 504

Paoletti, Rodolfo, see Vanhoutte, Paul M. 4
Patil, Popat N. and Beal, Jack L., Activities of *Thalictrum* alkaloids 327
Persson, Carl, Cromoglicate, plasma exudation and asthma 202
Peters, J. A., see Lambert, J. J. 224
Pliška, Vladimir, Dose–response models: similarity with population growth dynamics 50
Porsolt, R. D., Traditional notions of psychopharmacology reassessed at new style meeting 118
Portoghese, Philip S., Could DAA modulate norephinephrine storage function? 18
Presek, Peter, see Aktories, Klaus 158
Preussmann, R. and Wiessler, M., The enigma of the organ-specificity of carcinogenic nitrosamines 185
Putney, Jr., James W., Calcium-mobilizing receptors 479

Ramachandran, J. and Ullrich, Axel, Hormonal regulation of protein tyrosine kinase activity 28
Rand, M. J., Pharmacology downunder 237
Rayevsky, K. S., Obituary: Vasiliy Vasilievich Zakusov 42
Regoli, D., Domenico Regoli replies 208
Rice, Peter J., Taylor, David A. and Fleming, Willam W., Rapid sampling of biological signals using a simple assembly language loop 332
Robertson, G. S. and Robertson, H. A., D_1 and D_2 dopamine agonist synergism: separate sites of action? 295
Robertson, H. A., see Robertson, G. S. 295
Rochefort, Henri, Do antiestrogens and antiprogestins act as hormone antagonists or receptor-targeted drugs in breast cancer? 126
Röhrkasten, Axel, see Hofmann, Franz 393
Rosen, N., see Dickson, R. B. 372
Rosenthal, Walter and Schultz, Günter, Modulations of voltage-dependent ion channels by extracellular signals 351
Ross, Svante B., Pharmacological and toxicological exploitation of amine transporters 227
Ross, Svante B., see Jackson, David M. 419

Saano, Veijo, see MacDonald, Ewan 77
Schmid, Beat, Old and new concepts in teratogenicity testing 133
Schmidt-Kastner, R., Neurotransmission and ischemia 169
Schmitz, Wilhelm, Scholz, Hasso and Erdmann, Erland, HUMANS V. ANIMALS: Effects of α- and β-adrenergic agonists, phosphodiesterase inhibitors and adenosine on isolated human heart muscle preparations 447
Schneider, Toni, see Hofmann, Franz 393
Scholz, Hasso, see Schmitz, Wilhelm 447
Schultz, Gunter, see Rosenthal, Walter 351
Scott, Neil, 'Master–slave' demonstrations 207
Shankley, N. P., see Black, J. W. 484
Sieber, Manfred, see Hofmann, Franz 393
Sinclair, John David, Recycling random numbers 253
Smith, Peter F., see Brendel, Klaus 11
Sokolovsky, Mordechai, see Cohen, Sasson 41
Somogyi, Andrew, New insights into the renal secretion of drugs 354
Sontag, Karl-Heinz, see Klockgether, Thomas 20
Spedding, M., Three types of Ca^{2+} channel explain discrepancies 115
Srinivasan, B. D., see Kulkarni, Prasad 375
Stephenson, J. A., see Summers, R. J. 272
Story, D. F. and Ziogas, J., Interaction of angiotensin with noradrenergic neuroeffector transmission 269
Striessnig, Jörg, see Glossmann, Hartmut 95
Summers, R. J., Molenaar P. and Stephenson,

J. A., Autoradiographic localization of receptors in the cardiovascular system 272
Szabo, S. and Szelenyi, I., 'Cytoprotection' in gastrointestinal pharmacology 149
Szelenyi, I., see Szabo, S. 149

Taylor, Colin W., Receptor regulation of calcium entry 79
Taylor, David A., see Rice, Peter J. 332
Testa, Bernard, Pharmacokinetic and pharmacodynamic events: can they always be distinguished? 381
Thalabard, Jean-Christophe, see Thomas, Guy 292
Thomas, John M. and Hoffman, Brian B., Adenylate cyclase supersensitivity: a general means of cellular adaptation to inhibitory agonists? 308
Thomas, Guy, Thalabard, Jean-Christophe and Girre, Catherine, A program for the integrated Michaelis-Menten equation 292
Thompson, N. T., see Garland, L. G. 334
Tippins, John R., see di Marzo, Vincenzo, 168
Toda, Noboru, Is histamine a human coronary vasospastic substance? 289
Traber, Jörg and Glaser, Thomas, 5-HT_{1A} receptor-related anxiolytics 432
Trainor, Diane Amy, Synthetic inhibitors of human neutrophil elastase 303
Traynor, John R., Prodynorphin as a source of [Leu]enkephalin 47
Trethewey, John, Moving away from animal tests for the standardization of insulin formulations 287
Tuomanen, Elaine, Antibiotics which kill nongrowing bacteria 121
Turek, Fred W., Pharmacological probes of the mammalian circadian clock: use of the phase response curve approach 212
Turski, Lechoslaw, see Klockgether, Thomas 20

Uddman, R., see Edvinsson, L. 231
Udgaonkar, Jayant B. and Hess, George P., Isosteric regulation of the acetylcholine receptor 190
Udgaonkar, Jayant B., see Hess, George P. 335
Ullrich, Axel, see Ramachandran, J. 28
Unwin, A. R., Pharmacology and statistics: the Bloody Oblivious tester 420
Usowicz, Maria M., see Cull-Candy, Stuart G. 218

Vallotton, M. B, The renin-angiotensin system 69
Vane, J. R., Gryglewski, R. J. and Botting, R. M., The endothelial cell as a metabolic and endocrine organ 489
Vanhoutte, Paul M. and Paoletti, Rodolfo, The WHO classification of calcium antagonists 4
Vanhoutte, P. M., see Flavahan, N. A. 124
Vanhoutte, P., see Moncada, S. 365
Venter, J. Craig, see Kerlavage, Anthony R. 426
Vogel, W. H., Stress – the neglected variable in experimental pharmacology and toxicology 35

Wade, Denis, see Dougan, Donald 277
Wahlestedt, C., see Edvinsson, L. 231
Wallmark, Björn, see Lindberg, Per 399
Waltner, W. E., Boucher, R. C., Gatzy, J. T. and Knowles, M. R., Pharmacotherapy of airway disease in cystic fibrosis 316
Wanstall, Janet C., see O'Donnell, Stella R. 265
Weinbaum, George and Damiano, Victor V., Protease inhibitor therapy in emphysema: a promising theory with problems 6
Weston, Arthur H. and Abbott, Alison, New class of antihypertensive acts by opening K^+ channels 283
Wiessler, M., see Preussmann, R. 185
Williams, Michael, Receptor nomenclature: how, who and when? 251
Williams, Michael, see Jarvis, Michael F. 330
Winger, Gale, PCP–NMDA connection provides hope in cerebral ischemia but new direction for antipsychotics 323
Wolff, B., Dickson, R. B. and Hanover, J. A., A nuclear localization signal in steroid hormone receptors? 119
Woodruff, G. N. see Kemp, J. A. 414

Yanagisawa, Mitsuhiko, see Otsuka, Masanori 504

Zbinden, Gerhard, see Fent, Karl 100
Zbinden, Gerhard, Assessment of hyperplastic and neoplastic lesions of the thyroid gland 509
Ziogas, J., see Story, D. F. 269
Zorn, J., see Fleckenstein, A. 494
Zubensko, George S., see Etienne, Pierre E. 329

Subject index

Acetylcholine
  and circadian rhythm 214
  determination methods 84
Acetylcholine receptors
  central nicotinic 32
  inhibition of 294, 335
  muscarinic 41, 411
  regulation of 190, 294
Acidic amino acid receptors, classification 91
Acquired immune deficiency syndrome (AIDS) 339
ACTH, and adenylate cyclase supersensitivity 308
Actin, ADP-ribosylation of 158
Acute myocardial infarction 1
Addiction, cellular model 308
Adenosine
  and asthma (Letter) 52
  and dopamine 330
  and heart disease 450
Adenosine antagonists 330
Adenosine receptors, classification 91
Adenylate cyclase
  and G proteins 480
  regulation of 299
  supersensitivity of 308
Adrenaline (see Epinephrine)
α-Adrenergic agonists
  and cAMP production 21
  clonidine 244
  and human heart muscle 447
  and insulin secretion (α_2) 369
α-Adrenergic receptors
  downregulation of 310
  in human saphenous vein 358
  subclassification (α_1) (Letters) 123, 124
β-Adrenergic agonists, and human heart muscle 447
β-Adrenergic receptors
  and ageing 265
  and G proteins 300
  genetic sequencing of human 428
  in human saphenous vein 403
  localization 358
  and protein phosphorylation 272
  regulation of subtypes 265
Adrenocorticotrophic hormone, and memory 67
Ageing, and β-adrenergic receptors 265
Aggression 88
Airway hyperreactivity 8
Airway neuropeptides 24, 168
Alcoholism 161
Aldosterone 69
Alfaxalone 224
Alkaloids *(Thalictrum)* 327
Alkylating agents 187
Allopurinol, for Duchenne muscular dystrophy 111
Alprazolam 286
Alzheimer's disease 325
Amezinium 228
Amiloride 318
Amine transporters 227
Amphetamine
  and human psychosis 277
  and memory 67
Amrinone, and heart failure 447
Anabolic steroids, for Duchenne muscular dystrophy 111
Anaesthetics
  general 169
  local, and Na^+ channels 57
  steroids 224
Angiotensin I-converting enzyme 69
Angiotensin II
  and catecholamine 412
  and noradrenaline 269
Angiotensin II receptors, signal transduction 48
Angiotensinogen 69
Animals
  experimental use 78
  tests for insulin formulations 287
  welfare (Letter) 380
Aniracetam 66
Anisoylated plasminogen streptokinase activator complex (APSAC) 1
Annual rye grass, toxicity 263
Anorexia, and benzodiazepines 181
Antacids 151
Antiarrhythmics, and Na^+ channels 57
Antibiotics
  for non-growing bacteria 121
  Thalictrum alkaloids 329
Anticancer drugs, screening 249
Anticonvulsants
  benzodiazepines 180
  and Na^+ channels 57
Antidepressants 347
Antiestrogens, and breast cancer 126
Antihistamines 247
  (see also histamines)
Antihypertensives, and K^+ channels 283
Antiprogestins, and breast cancer 126
Antipsychotic drugs 388
Antiulcer drugs 151, 399
Antiviral agents 339
Anxiety, animal models 157, 383
Anxiolytics
  benzodiazepines 157, 180
  5-HT_{1A} receptor ligands 432
Appetite, and benzodiazepines 181
Arsenious oxide 419
Arteriosclerosis 496
Ascorbic acid, and neuronal function (Letter) 18
Aspirin 292
Astemizole 248
Asthma
  adenosine-induced (Letter) 52
  and airway hyperreactivity 8
  and airway neuropeptides 24, 168
  and cromoglicate 202
  and platelet-activating factor 285
Atrial natriuretic hormone 71
Australia
  history of pharmacology 237
  veterinary toxicology 262
Autopsy samples, of coronary arteries 289
Autoradiography, of receptors 272
Azidopine, for Ca^{2+} channel labelling 95, 395
AZT, see zidovudine

Barbiturates, and $GABA_A$ receptors 224
Batrachotoxinin A, and Na^+ channels 57
Bay K 8644 116
Belladonna 418
Benzodiazepine antagonists 180
Benzodiazepines 107, 157, 180, 349
  and circadian rhythm 216
Binding selectivity profiles, of opioid receptors 456
Botulinum toxins, ADP-ribosylation of actin 158
Bradykinin 71
Bromobenzene, experimental technique 14
α-Bungarotoxin, and nicotinic acetylcholine receptors 32
Buspirone 157, 384, 432, 504

Calcium 166
  and Duchenne muscular dystrophy 111
  mobilization 79, 481
Ca^{2+} antagonists 200
  and arteriosclerosis 496
  and Ca^{2+} channels 115
  WHO classification 4
Ca^{2+} channels
  in classification of Ca^{2+} antagonists 4
  photoaffinity labelling of 95
  types 115
  L-type 393
Caffeine 417
Calciton gene-related peptide 27
Cancer
  of breast 126, 372
  and cytotoxic drug-induced emesis 44
  and nitrosamines 185
  and radiation 17
  screening drugs for 249
Captopril 71, 269, 329
Cardiovascular system
  and neuropeptide Y 231
  receptor localization 272
Catecholamine 411
cDNAs, of receptors 198
Cell cultures, for screening anticancer drugs 249
cGMP-gated conductance 312
CGP 31608 (penem) 121
Chlorpromazine, in ion channel studies 459
Cholera toxin, ADP-ribosylation of actin 159
Cholescystokinin (CCK) 415
Cholescystokinin receptors, classification (Letter) 207
Cholesterol 442
Choline, determination methods 84
Cholinergic drugs, for memory and cognition 65
Chromaffin cells, muscarinic responses of 411
Cimetidine 354
Circadian rhythms 212
Cisplatin, emesis induced by 44
Clonidine, discontinuation syndrome 244
Clover, infertility induced by 262
Cognition, drugs for 65
Colestyramine, and coronary heart disease 442
Congestive heart failure 447
Coronary heart disease 442
Coronary vasospasm 289
Corynetoxins 263
Cromoglicate, and asthma 202
Cystic fibrosis 316
Cytoprotection, gastric 149

Deamino-oxytocin, agonist/antagonist–receptor interactions 336
Decamethonium 468

Dehydroascorbic acid, and neuronal function (Letter) 18
Desensitization
and adenylate cyclase activity 308
of β-adrenergic receptors 302, 475
of nicotinic acetylcholine receptors 464, 466
Dialysis 87
Diazepam 435
Dichlorobenzene, experimental technique 14
2',3'-dideoxynucleoside analogs 339
Dihydropyridines, for Ca^{2+} channel labelling 97
Dihydroxytryptamine 229
Diltiazem 116
Discontinuation syndrome, and clonidine 244
Diuretics 354
L-Dopa (levodopa) 295
Dopamine, and adenosine 330
Dopamine agonists (D_1, D_2) 295, 419
Dopamine receptors
classification 91
and (±)-tetrahydropalmatine 81
and *Thalictrum* alkaloids 328
Dose–response models 50
Drug delivery 138
Drug surveillance (post-marketing) (Letter) 52
Drug toxicity 258
Drugs
addiction 308
antihypertensive 283
antipsychotic 388
anxiolytic 180, 432
cholinergic 65
for cognition 65
discontinuation syndrome 244
hypocholesterolemic 442
for memory 65
photoactivatable 138
psychotropic 346
DSP4 (*N*-2-chloroethyl-*N*-ethyl-2-bromobenzylamine) 45, 230
Duchenne muscular dystrophy 109

Efficacy, of nicotinic acetylcholine receptors 464
Elastase, inhibitors 6, 303
Embryo culture, for teratogenicity tests 135
Emphysema, protease inhibitor therapy for 6, 303
Enalapril 71, 117
Endothelial cells 491
Endothelium-derived relaxing factor (EDRF) 365, 491
[Leu]Enkephalin 47
Epidermal growth factor (EGF), and protein tyrosine kinase 28
Epidermal growth factor–urogastrone receptor (EGFR), cDNA 198
Epinephrine (adrenaline)
and memory 67, 83
and stress 35
Epipolythiodioxopiperazine toxins 144
Epithelium
and airway hyperreactivity 8
and ion transport 316
Epithelium-derived inhibitory substance 8
Ethanol
interaction with environment 161
toxicity 258
Ethylcholine aziridinium ion (AF64A) 45
Etiracetam 66

Fenfluramine 199
Fiber dialysis 87
Flumazepil (Ro 15-1788), and circadian rhythm 216
Flunarizine 116
Fluoxetine 199
Foods, toxicity 258
Free radicals, and Duchenne muscular dystrophy 111
Furosemide 254

G proteins 478
in adenylate cyclase model 299
and adenylate cyclase supersensitivity 308
and ion channels 312, 353
subunits 209
GABA (γ-aminobutyric acid)
and cAMP production 21
and circadian rhythm 214
uptake sites 200
$GABA_A$ receptors, and steroids 224
Galanin 27
Gallopamil 200
Gastric acid secretion, permission and transmission hypotheses 487
Gastric acid secretion inhibitors (antiulcer drugs) 399
Gastric cytoprotection 149
Gastrin 486
Gepirone, and anxiety 432
Ginkgolides 286, 290
Glucocorticoid receptors 10, 119
Glutamate receptor channels 218
Glutamate receptors (Meeting Report) 243
Glycine receptors 204, 379
GR 38032F, anti-emetic effect 44
Guanine nucleotide-binding regulatory proteins (see G proteins)

H-7 (1-(5-isoquinolinesulfonyl)-2-methylpiperazine), inhibition protein kinase C 163
Haloperidol 346
Hematoporphyrin 142
15-HETE (15-hydroxy-5, 8, 11, 13-eicosatetraenoic acid) 491
Hexamethonium 465
Histamines
and coronary vasospasm 289
and gastric acid secretion 151, 486
H_1/H_2 agonists 437
H_1 receptors 247
H_2 antagonists 151, 486
H_2 receptors 200
and immunity 437
(see also antihistamines)
HMG-CoA reductase inhibitors 442
13-HODE (13-hydroxy-9, 11-octadecadienoic acid) 491
5-HT (5-hydroxytryptamine) 501
and anxiety 157, 383
and human saphenous vein 358
and psychotropic drugs 105
and sweet taste 199
5-HT agonists 199, 501
(see also individual drugs)
$5\text{-}HT_{1A}$ receptor ligands, and anxiety 432
5-HT receptors
and Ca^{2+} antagonists ($5\text{-}HT_2$) 200
classification 90, 501
and drug-induced emesis ($5\text{-}HT_3$) 44
Human neutrophil elastase, inhibitors 6, 303
Human saphenous vein 358
Hydra, for teratogenicity tests 134
Hydralazine 283
6-Hydroxydopamine 229, 265
Hypertension, and Ca^{2+} 500
Hypocholesterolemic agents 442

ICS 205–930, anti-emetic effect 44
Imipenem 121
Inositol lipids
and Ca^{2+} mobilization 79, 481
and lithium 129
Inositol-1,4,5-trisphosphate ($1,4,5IP_3$), and Ca^{2+} regulation 79, 481
Insulin
and α_2-adrenergic agonists 369
formulations 287
and protein tyrosine kinase 28
Insulin receptors
cDNA 198
and protein phosphorylation 475
Insulin-like growth factor 1 (IGF-1)
and protein tyrosine kinase 28
receptor cDNA 198
Interferon, toxic effects 100
Interleukin, toxic effects 100
Ion channels 312, 351, 395, 459, 480
(see also individual ions)
Ipsapirone, and anxiety 384, 432
Ischemia (cerebral)
and neurotransmission (Letter) 169
and MK-801 414
and NMDA 414
Isoflavones 262
Isoquinoline sulfonamide protein kinase C inhibitors 162

Jet lag 217

K^+ channel opener 283
Ketamine 223
Ketanserin 106, 503
Ketoacids (branched chain), and Duchenne muscular dystrophy 112

β-Lactam antibiotics 121
Leukotrienes, and asthma (Letter) 168
Lithium
and 5-HT 107
and inositol lipids 129
Lovastatin 442
Luciferase 173

Malnutrition 258
MDL 72222, anti-emetic effect 44
Memory
drugs for 65
and epinephrine 83
Mental retardation, animal models 165
Mequitazine 248
Methimazole 512
Metoclopramide, anti-emetic effect 44
Methylazoxymethanol 165
α-Methyltyramine 277
Mevastatin 442
Michaelis–Menten equation 292
Microbial toxins, ADP-ribosylation of actin 158
Microdialysis 87
Minoxidil 117, 283
MK-801 244, 324, 414
Monoamine oxidase (MAO) inhibitors 228, 349, 387
Mortality 291
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) 7, 45, 230
Muscarinic agonists, and gastric acid secretion 489
Muscarinic cholinergic receptors
and catecholamine secretion 411
cDNA 198
downregulation 310
genetics and structure 426
history 41
Muscular dystrophy (Duchenne) 109
Myocardial infarction, acute 1

Na^+ channels, and drugs 57
Na^+/Ca^{2+} exchange, and Duchenne muscular dystrophy 112
NANC (non-adrenergic non-cholinergic) nerves 24, 231
Naloxone, and memory 67
Neurokinins (tachykinins) 26
see also individual entries
Neuroleptics 388
Neuropathy target esterase 174
Neuropeptide Y
in airway nerves 27
and the cardiovascular system 231
and circadian rhythm 214
Neuropeptides, and asthma 24, 168
Nicotinic acetylcholine receptors 32, 465
cDNA 198
ion channel 459
and protein phosphorylation 472
Nitric oxide 365
Nitrosamines, organ-specificity 185
NMDA (*N*-methyl-D-aspartate) receptor antagonists 20
NMDA receptor channels 219
NMDA receptors 20
Nootropics 65, 118
Noradrenaline, and angiotensinogen II 269
Nuclear transport signals 119

Ocular inflammation 375
8-OH-DPAT 106, 199, 385, 435, 503
Omeprazole 399
Opiate receptors, downregulation 310
Opioid receptors
binding selectivity profiles 456
[Leu]enkephalin 47
and rumination 168
Organic nitrates 367
Organophosphate-induced delayed polyneuropathy 174

Organophosphates 174
Oxygen, toxicity 258
Oxytocin 336

Palatability, and 5-HT receptors 199
Palmitoyl carnitine 117
Paracelsian doctrine 258
Parathyroid hormone 246
Parkinson's disease
  and dopamine agonists 296
  and MPTP 7
Pentagastrin 486
Pepstatin 71
Peptide histidine isoleucine, and asthma 25
Peptide T 340
Perfringens iota toxin, ADP-ribosylation of actin 160
Pertussis toxin, ADP-ribosylation of actin 159
Pharmacodynamics 381
Pharmacokinetics 381
Pharmacology, in Australia 237
Phase response curves, for circadian rhythms 213
Phenothiazines 347
Phenycyclidine 243, 323
Phenycyclidine/sigma receptors 243
Phenytoin, and Na^+ channels 62
Phosphatidylinositol, metabolism 79, 481
Phosphodiesterase inhibitors 447
Phosphoinositides, history 53
Phospholipase A, and cAMP production 21
Phospholipase C, and G proteins 480, 483
Photoactivatable drugs 138
Photoaffinity probes 95
Photoreceptors 312
Photosensitizers 139
Pinacidil 283
Piracetam 66
Pirenzepine, and muscarinic receptors 42
Platelet-activating factor (PAF) 491
  antagonists 286
  and asthma 285
Platelet-derived growth factor (PDGF)
  and protein tyrosine kinase 28
  receptor cDNA 198
Population growth dynamics 50
Potassium (see K^+)
Pramiracetam 66
Probenecid 354
Prodynorphin 47
Progesterone metabolites, and GABA 224, 334
(−)-Propranolol, and anxiety 384
Prostacyclin 367, 491
Prostaglandin 256
Protease inhibitor, and emphysema 6
Protein kinase C
  and cAMP production 21
  inhibitors 162, 334
Protein phosphorylation, and receptor regulation 472
Protein tyrosine kinase, hormonal regulation of 28
Proto-oncogenes, in breast cancer 372
Psoralen, and cutaneous T-cell lymphoma 141
Psychopharmacology (Meeting Report) 118
Psychotropic drugs, perinatal neurotoxicology of 346
Puffer fish, tetrodotoxin from 16

Pyrazoloquinolines 180

Quipazine 200

Radiation hazards 17
Radioligands, binding curves 421
Random numbers (Letter) 253
Random sampling 332
Ras gene, and breast cancer 374
Receptors
  agonist–antagonist interactions 336
  autoradiographic localization 272
  binding selectivity profiles 456
  chimeric 30
  classification 90, 251, 368, 377, 471
  desensitization 190
  regulation 21
    by protein phosphorylation 472
    classification 476
  single channel recording 218
  structure–activity relationships 197
  (see also named entries)
Recombinant tissue type plasminogen activator (rt-PA) 1
Reinforced behavior, quantification 388
Renin–angiotensin system 69, 269, 371
Reperfusion, of infarcted myocardium with streptokinase 2
Re-uptake mechanisms, for transmitter amines 227
Risk assessment 511
Ritanserin, and anxiety 158
Ro 15-1788, see flumazepil
RU486, and breast cancer 126

Saralasin 71, 269
Sarcolemmal Ca^{2+}-ATPase, and Duchenne muscular dystrophy 112
Scatchard analysis 421
Schizophrenia 277
Selenium deficiency, and Duchenne muscular dystrophy 111
Serotonin (see 5-HT)
Signal transduction 209, 312, 351
Single channel recording 218
(+)-SKF 10047 324
Sodium (see Na^+)
Statistics (Letters) 252, 420
Steroid receptors, domains 10, 119
Steroids
  and GABA receptors 224, 334, 380
  for Duchenne muscular dystrophy 111
Streptokinase, and infarcted myocardium 2
Stress 35
Structure–activity relationships 197
Strychnine, as probe 204, 379
Substance P
  antagonists 508
  and asthma 26
  and catecholamine secretion 413
  and memory 67
  as pain transmitter 506
  receptor localization 272
Supersensitivity, of adenylate cyclase 308
Suramin 341

T cells, and histamine 437
Tachykinins, see neurokinins
Tamoxifen 117
Taurine, and rat aggression 88
Teaching, use of video 78, 207
Teratogenicity tests 133
Terfenadine 248
(±)-Tetrahydropalmatine 81
Tetrodotoxin 16
Thalictrum alkaloids 327
Theophylline, and heart failure 447
Thrombogenesis 1
Thrombolysis 1
Thyroid tumors 511
Thyrotropin 511
Tissue culture
  slicing techniques 11
  for teratogenicity tests 133
Toxicity
  of batrachotoxinin A 60
  of botulinum 158
  of α-bungarotoxin 32
  of cholera 159
  of corynetoxins 263
  of epipolythiodioxopiperazine 144
  of ethanol 258
  of foods 258
  fungal 144
  of interferon 100
  of interleukin 100
  of isoflavones 262
  microbial 158
  of oxygen 258
  of perfringens iota toxin 160
  of pertussis toxin 159
  of tetrodotoxin 16
  of tunicamycin 264
Toxicology
  Paracelsian doctrine 258
  veterinary 262
Transmembrane signalling 30
Transmitter amines, re-uptake mechanisms 227
Triazolam, and circadian rhythm 216
Tricyclic antidepressants, effect on brain 5-HT 107
Tubocurarine 465
Tunicamycin 264
Tyrosine kinases, and breast cancer 373

Vasoactive intestinal peptide (VIP)
  and asthma 24
  and catecholamine secretion 412
Vasopressin, and memory 67
Verapamil 111, 116, 200
Veterinary toxicology 262

WR2721, for radioprotection 246

Xanthines, and bronchoconstriction (Letter) 52
Xenobiosis 258, 354
X-rays, risks 17
Xylamine 230

Zakusov, V. V. (Obituary 1903–86) 42
Zidovudine (AZT) 341
Zombies, and tetrodotoxin 16
Zopiclone 181